- Home
- CCXI vs CSTL Comparison
CCXI vs CSTL Comparison
Compare CCXI & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCXI | CSTL |
|---|---|---|
| Founded | 2025 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medical Specialities |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 664.2M | 722.8M |
| IPO Year | 2025 | 2019 |
Fundamental Metrics
Financial Performance| Metric | CCXI | CSTL |
|---|---|---|
| Price | $8.95 | $34.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $46.70 |
| AVG Volume (30 Days) | ★ 3.8M | 321.8K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $344,229,000.00 |
| Revenue This Year | N/A | $8.68 |
| Revenue Next Year | N/A | $12.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 3.66 |
| 52 Week Low | $8.11 | $17.72 |
| 52 Week High | $19.69 | $44.28 |
Technical Indicators
Market Signals| Indicator | CCXI | CSTL |
|---|---|---|
| Relative Strength Index (RSI) | 33.26 | 51.33 |
| Support Level | N/A | $33.90 |
| Resistance Level | $10.33 | $37.42 |
| Average True Range (ATR) | 0.50 | 1.76 |
| MACD | -0.10 | 0.33 |
| Stochastic Oscillator | 31.98 | 44.22 |
Price Performance
Historical ComparisonAbout CCXI Churchill Capital Corp XI Class A Ordinary Shares
Churchill Capital Corp XI is a blank check company.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.